Cellmid Announces That British Journal of Pharmacology Features Midkine
News Mar 08, 2014
Cellmid Limited advises that The British Journal of Pharmacology (BJP) has recently published a special edition dedicated to midkine (MK) including 16 research papers by various authors.
The BJP is the premier peer-reviewed publication of the British Pharmacological Society, and it is recognized as one of the most influential international journals covering all aspects of experimental pharmacology.
The BJP Midkine Issue contains invited reviews from pre-eminent MK researchers from around the world, with comprehensive up-to-date articles covering the gamut of MK biology. Publications examine the role of MK in diseases including various cancers, kidney diseases, cardiovascular disease, multiple sclerosis and neurodegenerative disorders. New understanding of MK signaling and receptors is also featured.
The full table of contents and the articles themselves can be viewed at
“Being featured in a high-impact, internationally regarded journal with a global audience is a strong validation of MK’s importance in health and disease”, said Cellmid CEO, Maria Halasz. “Cellmid recognized this potential early on, and it is pleasing to see the increasing and ever wider realization of MK’s potential utility as a disease target or as a therapeutic agent in its own right.”
“Having MK reviewed in this way is very helpful to Cellmid’s product development programs”, added Darren Jones, Head of Product Development. “Publications such as these provide strong supporting evidence to regulators, key opinion leaders and potential biotech and pharma partners. They provide a solid foundation upon which Cellmid can build its clinical programs and collaborations.”
Since its discovery in 1988, MK has been the subject of over 670 peer-review papers.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.